Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0MUIQK)
| ADC Name |
LFD-200
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
LFD-200
Click to Show/Hide
|
|||||
| Organization |
Lifordi Immunotherapeutics (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Antibody Name |
Anti-VISTA antibody
|
Antibody Info | ||||
| Antigen Name |
V-type immunoglobulin domain-containing suppressor of T-cell activation (VSIR)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
Payload Info | ||||
| Payload Target |
Glucocorticoid receptor (NR3C1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Rheumatoid arthritis |
1 Trials
|